What is HC Wainwright’s Estimate for CRBP FY2030 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research note issued to investors on Monday, March 9th. HC Wainwright analyst A. Maldonado anticipates that the biopharmaceutical company will post earnings of ($1.21) per share for the year. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings data on Monday, March 9th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($1.78) by $0.53.

Several other research analysts have also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Wednesday, January 21st. Jefferies Financial Group raised Corbus Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, February 18th. Oppenheimer boosted their target price on Corbus Pharmaceuticals from $53.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Royal Bank Of Canada reduced their target price on Corbus Pharmaceuticals from $55.00 to $53.00 and set an “outperform” rating for the company in a report on Thursday, November 13th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.71.

Corbus Pharmaceuticals Price Performance

NASDAQ CRBP opened at $10.43 on Wednesday. Corbus Pharmaceuticals has a 12 month low of $4.64 and a 12 month high of $20.56. The company has a market capitalization of $183.05 million, a P/E ratio of -1.74 and a beta of 2.84. The company’s 50 day simple moving average is $8.24 and its 200 day simple moving average is $10.54.

Insider Buying and Selling

In other Corbus Pharmaceuticals news, insider Dominic Smethurst sold 3,285 shares of Corbus Pharmaceuticals stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $8.09, for a total transaction of $26,575.65. Following the transaction, the insider directly owned 95,887 shares in the company, valued at approximately $775,725.83. The trade was a 3.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.60% of the company’s stock.

Institutional Trading of Corbus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. Persistent Asset Partners Ltd acquired a new position in Corbus Pharmaceuticals during the fourth quarter valued at $54,000. ADAR1 Capital Management LLC acquired a new stake in Corbus Pharmaceuticals during the 3rd quarter worth about $129,000. Virtu Financial LLC acquired a new stake in Corbus Pharmaceuticals during the 4th quarter worth about $88,000. Barclays PLC grew its stake in Corbus Pharmaceuticals by 280.0% during the 4th quarter. Barclays PLC now owns 14,758 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 10,874 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new position in shares of Corbus Pharmaceuticals in the 4th quarter valued at about $139,000. Institutional investors and hedge funds own 64.64% of the company’s stock.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.